SELLAS Life Sciences (SLS) EBITDA Margin Growth (1y) (2013 - 2022)
Powered by 
Analysis
SELLAS Life Sciences (SLS) EBITDA Margin Growth (1y) (2013 - 2022) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | -143.00 |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 78.00 |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 1,135.00 |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 7,666.00 |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 1,238.00 |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 2,002.00 |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | -1,651.00 |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 29,091.00 |
| 10 | SELLAS Life Sciences | 2.64 Bn | 2.64 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | -163,411.00 |
| Jun 30, 2015 | 40,852.00 |
| Mar 31, 2015 | 22,121.00 |
| Dec 31, 2014 | -8,432.00 |
| Sep 30, 2014 | -22,679.00 |
| Jun 30, 2014 | -33,449.00 |
| Mar 31, 2014 | -24,105.00 |
| Dec 31, 2013 | -69,581.00 |
| Sep 30, 2013 | 4,698.00 |